CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
The Bitter Truth: Alcohol Use and Its Effects on Chemosensory Function , homeOct. 3, 2025, 11:00 a.m. | Paule Valery Joseph, Ph.D., Lasker Clinical Research Scholar, NIH Distinguished Scholar; Acting Chief, Section of Sensory Science and Metabolism Unit, Co-Director of the National Smell and Taste Center, National Institute on Deafness and Other Communication Disorders; National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center
-
Home Item
Organization and Control of Hippocampal Networks , homeOct. 17, 2025, 11:00 a.m. | Ivan Soltesz, Ph.D., James R. Doty Professor of Neurosurgery and Neurosciences, Stanford University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home Item
Maury Strauss Distinguished Public Lecture , homeOct. 30, 2025, 5:30 p.m. (Reception at 5 p.m.) | Jennifer Munson, Ph.D., Professor and Director, Cancer Research Center — Roanoke, Fralin Biomedical Research Institute; Professor, Department of Biomedical Engineering and Mechanics, Virginia Tech College of Engineering | Maury Strauss Distinguished Public Lecture
-
Home Item
Thinking the Right Thoughts , homeOct. 31, 2025, 11 a.m. | Nathaniel Daw, Ph.D., Professor, Computational and Theoretical Neuroscience, Department of Psychology, Princeton University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
Maury Strauss Distinguished Public Lecture , homeNov. 6, 2025, 5:30 p.m. (Reception at 5 p.m.) | Teresa Lambe, Ph.D., OBE, Calleva Head of Vaccine Immunology, Professor of Vaccinology and Immunology, University of Oxford | Maury Strauss Distinguished Public Lecture
-
Home Item
Understanding Vascular Morphogenesis and Morphology: Live Insights from Zebrafish , homeNov. 21, 2025, 11:00 a.m. | Arndt F. Siekmann, Ph.D., Associate Professor, Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania | Co-Sponsored by the Center for Vascular and Heart Research, Fralin Biomedical Research Institute